期刊
ARCHIVES OF OPHTHALMOLOGY
卷 128, 期 11, 页码 1449-1454出版社
AMER MEDICAL ASSOC
DOI: 10.1001/archophthalmol.2010.265
关键词
-
资金
- National Science Foundation [30630064]
- National Supporting Project of China [2007BAI18B10]
- National Nature Science Foundation [30973242]
- Health Bureau of Chongqing [2008115]
- Medical Science and Technology of Chongqing [2008-1-15]
- Nature Science Foundation of Chongqing [2009BA5037]
- Chongqing Key Laboratory of Ophthalmology [2008CA5003]
- Chongqing Municipality
Objectives: To analyze the expression and potential role of interleukin (IL) 21 in the pathogenesis of Vogt-Koyanagi-Harada (VKH) disease. Methods: Blood samples were obtained from patients with VKH disease and from healthy control subjects. Serum IL-21 level and IL-21 messenger RNA (mRNA) expression by peripheral blood mononuclear cells (PBMCs) were determined by enzyme-linked immunosorbent assay and by reverse transcriptase-polymerase chain reaction, respectively. Interleukin 17 and interferon gamma levels in the supernatants of PBMCs and CD4(+) T cells cultured with anti-CD3 and anti-CD28 antibodies in the presence or absence of recombinant IL-21 were detected by enzyme-linked immunosorbent assay. Results: The results showed a significantly increased serum IL-21 level, as well as higher IL-21 mRNA expression by PBMCs, in patients having chronic or recurrent active VKH disease compared with patients having inactive VKH disease and with controls. In vitro experiments showed that recombinant IL-21 significantly increased IL-17 production by PBMCs and by CD4(+) T cells from patients and from controls. However, recombinant IL-21 did not affect interferon gamma expression by PBMCs or by CD4(+) T cells. Conclusion: Interleukin 21 may be involved in the pathogenesis of chronic or recurrent VKH disease, possibly by promoting IL-17 secretion. Clinical Relevance: Findings from the present study suggest that IL-21 may be a potential target in the development of therapy for VKH disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据